Products
Tamrintamab Pamozirine Biosimilar Antibody-Drug Conjugate (DPEP3) for Research
Pre-made Tamrintamab Pamozirine benchmark antibody (Whole mAb ADC, anti-DPEP3 therapeutic antibody, Anti-MBD3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1006-1mg | 1mg | |
| GMP-Bios-INN-1006-10mg | 10mg | |
| GMP-Bios-INN-1006-100mg | 100mg | |
| GMP-Bios-INN-1006-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tamrintamab Pamozirine Biosimilar, Whole Mab Adc, Anti-Dpep3 Antibody: Anti-MBD3 therapeutic antibody Drug Conjugate |
| INN Name | Tamrintamab Pamozirine |
| Target | DPEP3 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | AbbVie Inc. (North Chicago IL USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - DPEP3
1. Protein Dipeptidase 3
2. Gene DPEP3
3. Organism Homo sapiens (Human)
Function
Dipeptidase that hydrolyzes cystinyl-bis-glycine. Does not hydrolyze leukotriene D4 (LTD4) into leukotriene E4 (LTE4).
Catalytic activity
an L-aminoacyl-L-amino acid + H2O = 2 an L-α-amino acid
EC:3.4.13.19
Source: Rhea.
2 H2O + L-cystine-bis-glycine = 2 glycine + L-cystine
Source: Rhea.
Cofactor
Zn2+
Activity regulation
Inhibited by L-penicillamine.
